Filing Flows › Collegium Pharmaceutical (COLL) › Guidance history
Collegium Pharmaceutical (COLL) guidance history: what it guided and what it reported
Collegium Pharmaceutical gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance once and lowered it once.
Adjusted EBITDA
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $455M–$475M (May 7, 2026) → lowered $445M–$470M (Aug 6, 2026) → reaffirmed $445M–$470M (Nov 5, 2026) | — | to be reported | — |
The latest quarter
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.
Questions
Does Collegium Pharmaceutical beat its guidance?
Collegium Pharmaceutical gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance once and lowered it once.
How often does Collegium Pharmaceutical raise guidance?
Its earnings releases raised guidance once and lowered it once since May 7, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.